HKUCTR-2992Not yet recruiting
Untitled Trial
Ancillary study evaluating ChAd155-hIi-HBV shedding in a subset of chronic hepatitis B patients enrolled in the first-time-in-human, Phase I, randomised, multi-centric, single-blind study TH HBV VV-001.
GlaxoSmithKline Biologicals SAPhase 1HKU CLINICAL TRIALS REGISTRY
VerifiedHKU CLINICAL TRIALS REGISTRY
Study focus
- Disease/Condition
- Infection
- Study type
- Observational
Sponsor & location
- Primary sponsor
- GlaxoSmithKline Biologicals SA
- Location
- China
Timeline & enrollment
- Phase
- Phase 1
- Start date
- N/A
- End date
- Dec 31, 2021
ICD-10 classifications
Bacterial infection, unspecifiedBacterial, viral and other infectious agentsInfection following immunizationOther infectious diseasesViral infection, unspecified
Data source
- Registry
- HKU CLINICAL TRIALS REGISTRY
- Trial ID
- HKUCTR-2992
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for HKUCTR-2992 through Pure Global AI's free database. This Phase 1 trial is sponsored by GlaxoSmithKline Biologicals SA and is currently Not yet recruiting. The study focuses on Infection.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to HKU CLINICAL TRIALS REGISTRY data, helping medical device and pharmaceutical companies navigate clinical research efficiently.